These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35279606)

  • 21. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
    Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
    Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pimavanserin use in a movement disorders clinic: a single-center experience.
    Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N
    Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
    Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
    J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pimavanserin exhibits serotonin 5-HT
    Muneta-Arrate I; Diez-Alarcia R; Horrillo I; Meana JJ
    Eur Neuropsychopharmacol; 2020 Jul; 36():83-89. PubMed ID: 32517960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pimavanserin, a 5HT
    Yuede CM; Wallace CE; Davis TA; Gardiner WD; Hettinger JC; Edwards HM; Hendrix RD; Doherty BM; Yuede KM; Burstein ES; Cirrito JR
    J Neurochem; 2021 Mar; 156(5):658-673. PubMed ID: 33278025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
    Hermanowicz S; Hermanowicz N
    Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
    Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
    Ballard CG; Kreitzman DL; Isaacson S; Liu IY; Norton JC; Demos G; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2020 Aug; 77():100-106. PubMed ID: 32712560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pimavanserin as treatment for Parkinson's disease psychosis.
    Fox SH
    Lancet; 2014 Feb; 383(9916):494-6. PubMed ID: 24183566
    [No Abstract]   [Full Text] [Related]  

  • 34. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
    Abbas A; Roth BL
    Expert Opin Pharmacother; 2008 Dec; 9(18):3251-9. PubMed ID: 19040345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trial of Pimavanserin in Dementia-Related Psychosis.
    Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
    N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A New Hope in Alzheimer's Disease Psychosis: Pimavanserin.
    Kurhan F; Akın M
    Curr Alzheimer Res; 2023; 20(6):403-408. PubMed ID: 37641988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
    Nasrallah HA; Fedora R; Morton R
    Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can pimavanserin help patients with Parkinson disease psychosis?
    de la Cruz J; Canal C
    JAAPA; 2019 Jan; 32(1):44-45. PubMed ID: 30589736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
    Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ
    Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.